165 related articles for article (PubMed ID: 29607978)
41. Multidetector-row computed tomography is useful to evaluate the therapeutic effects of bisphosphonates in glucocorticoid-induced osteoporosis.
Inoue K; Hamano T; Nango N; Matsui I; Tomida K; Mikami S; Fujii N; Nakano C; Obi Y; Shimomura A; Kusunoki Y; Rakugi H; Isaka Y; Tsubakihara Y
J Bone Miner Metab; 2014 May; 32(3):271-80. PubMed ID: 23832575
[TBL] [Abstract][Full Text] [Related]
42. Comparison of non-vertebral fracture between minodronate and risedronate therapy in elderly female patients with Alzheimer disease.
Sato Y; Honda Y; Iwamoto J; Amano N
J Musculoskelet Neuronal Interact; 2013 Sep; 13(3):346-52. PubMed ID: 23989256
[TBL] [Abstract][Full Text] [Related]
43. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.
Sambrook PN; Roux C; Devogelaer JP; Saag K; Lau CS; Reginster JY; Bucci-Rechtweg C; Su G; Reid DM
Bone; 2012 Jan; 50(1):289-95. PubMed ID: 22061864
[TBL] [Abstract][Full Text] [Related]
44. Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis.
Cairoli E; Eller-Vainicher C; Ulivieri FM; Zhukouskaya VV; Palmieri S; Morelli V; Beck-Peccoz P; Chiodini I
Osteoporos Int; 2014 Apr; 25(4):1401-10. PubMed ID: 24510095
[TBL] [Abstract][Full Text] [Related]
45. Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA).
Matsumoto T; Yamamoto K; Takeuchi T; Tanaka Y; Tanaka S; Nakano T; Ito M; Tomomitsu T; Hirakawa A; Soen S
J Bone Miner Metab; 2020 Jul; 38(4):522-532. PubMed ID: 32140784
[TBL] [Abstract][Full Text] [Related]
46. Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial.
Mok CC; Ho LY; Ma KM
Bone; 2015 Jun; 75():222-8. PubMed ID: 25761434
[TBL] [Abstract][Full Text] [Related]
47. Changes in bone mineral density after kidney transplantation: 2-year assessment of a French cohort.
Segaud N; Legroux I; Hazzan M; Noel C; Cortet B
Osteoporos Int; 2018 May; 29(5):1165-1175. PubMed ID: 29500526
[TBL] [Abstract][Full Text] [Related]
48. The importance of assessing the rate of bone turnover and the balance between bone formation and bone resorption during daily teriparatide administration for osteoporosis: a pilot study.
Nakatoh S
J Bone Miner Metab; 2016 Mar; 34(2):216-24. PubMed ID: 26031934
[TBL] [Abstract][Full Text] [Related]
49. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis.
Tan W; Sun J; Zhou L; Li Y; Wu X
J Clin Pharm Ther; 2016 Oct; 41(5):519-23. PubMed ID: 27440710
[TBL] [Abstract][Full Text] [Related]
50. Bone Mineral Density and Bone Turnover Markers Under Bisphosphonate Therapy Used in the First Year After Liver Transplantation.
Nowacka-Cieciura E; Sadowska A; Pacholczyk M; Chmura A; Tronina O; Durlik M
Ann Transplant; 2016 Apr; 21():241-9. PubMed ID: 27112626
[TBL] [Abstract][Full Text] [Related]
51. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
Burshell AL; Möricke R; Correa-Rotter R; Chen P; Warner MR; Dalsky GP; Taylor KA; Krege JH
Bone; 2010 Apr; 46(4):935-9. PubMed ID: 20060081
[TBL] [Abstract][Full Text] [Related]
52. Effects of denosumab on rheumatic diseases and refractory glucocorticoid-induced osteoporosis: a prospective study.
Ishida T; Yoshida S; Fujiki Y; Hata K; Kotani T; Takeuchi T
Arch Osteoporos; 2021 Feb; 16(1):39. PubMed ID: 33624165
[TBL] [Abstract][Full Text] [Related]
53. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.
Langdahl BL; Marin F; Shane E; Dobnig H; Zanchetta JR; Maricic M; Krohn K; See K; Warner MR
Osteoporos Int; 2009 Dec; 20(12):2095-104. PubMed ID: 19350340
[TBL] [Abstract][Full Text] [Related]
54. Bone turnover markers as an aid to monitor osteoporosis following allogeneic hematopoietic stem cell transplantation.
Kurosawa S; Doki N; Senoo Y; Kishida Y; Nagata A; Yamada Y; Konishi T; Kaito S; Yoshifuji K; Matsuyama N; Shirane S; Uchida T; Inamoto K; Toya T; Igarashi A; Najima Y; Muto H; Kobayashi T; Kakihana K; Sakamaki H; Ohashi K
Ann Hematol; 2020 Aug; 99(8):1873-1882. PubMed ID: 32451708
[TBL] [Abstract][Full Text] [Related]
55. Effects of bisphosphonate administration on the bone mass in immune thrombocytopenic purpura patients under treatment with steroids.
Nomura S; Kurata Y; Tomiyama Y; Takubo T; Hasegawa M; Saigo K; Nishikawa M; Higasa S; Maeda Y; Hayashi K
Clin Appl Thromb Hemost; 2010 Dec; 16(6):622-7. PubMed ID: 19959489
[TBL] [Abstract][Full Text] [Related]
56. Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial.
Hakala M; Kröger H; Valleala H; Hienonen-Kempas T; Lehtonen-Veromaa M; Heikkinen J; Tuomiranta T; Hannonen P; Paimela L;
Scand J Rheumatol; 2012 Aug; 41(4):260-6. PubMed ID: 22803768
[TBL] [Abstract][Full Text] [Related]
57. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM
Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963
[TBL] [Abstract][Full Text] [Related]
58. Comparison of the effects of 12 months of monthly minodronate monotherapy and monthly minodronate combination therapy with vitamin K2 or eldecalcitol in patients with primary osteoporosis.
Ebina K; Noguchi T; Hirao M; Kaneshiro S; Tsukamoto Y; Yoshikawa H
J Bone Miner Metab; 2016 May; 34(3):243-50. PubMed ID: 26303222
[TBL] [Abstract][Full Text] [Related]
59. Increased Serum 25(OH)D
Nakamura Y; Uchiyama S; Kamimura M; Ikegami S; Komatsu M; Kato H
Tohoku J Exp Med; 2017 Jul; 242(3):241-246. PubMed ID: 28740036
[TBL] [Abstract][Full Text] [Related]
60. The clinical benefits of denosumab for prophylaxis of steroid-induced osteoporosis in patients with pulmonary disease.
Ishiguro S; Ito K; Nakagawa S; Hataji O; Sudo A
Arch Osteoporos; 2017 Dec; 12(1):44. PubMed ID: 28425086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
